Biopharm Distribution SPA Pharmaceutical Import Profile — Algeria (DGFT 2022–2026)

Name: Biopharm Distribution SPA Pharmaceutical Import Records from India — 2 Products, $5.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biopharm Distribution SPA — Pharmaceutical Importer Profile (2026) | 2 Products, $5.6M Trade | TransData Nexus

Biopharm Distribution SPA

Pharmaceutical Importer · Algeria · Respiratory Focus · $5.6M Total Trade · DGFT Verified

Biopharm Distribution SPA is a pharmaceutical importer based in Algeria with a total trade value of $5.6M across 2 products in 1 therapeutic categories. Based on 112 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Biopharm Distribution SPA sources from 2 verified Indian suppliers, with Cipla Limited accounting for 99.8% of imports.

Biopharm Distribution SPA — Import Portfolio & Supplier Network

Biopharm Distribution SPA import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biopharm Distribution SPA?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$6.4M	245	99.8%
J B Chemicals And Pharmaceuticals Limited	$10.8K	1	0.2%

Biopharm Distribution SPA sources from 2 verified Indian suppliers across .

What Formulations Does Biopharm Distribution SPA Import?

Formulation	Value	Ships
Budecort 200 inhaler with dose	$1.4M	31
Budecort 200 inhaler with dose idicator (budesonide 200mcg) 1 x 200	$1.0M	21
Budecort 200 inhaler with dose idicator(budesonide 200 MCG	$541.1K	12
Budecort 200 inhaler with dose indicator(budesonide 200 MCG	$540.2K	12
Budecort 200 inhaler with dose idicatorbudesonide 200 MCG.	$400.0K	8
Budecort 200 inhaler with dose idicator(budesonide 200mcg) (1 x 200 md)	$200.0K	4
Budecort 200 inhaler with dose idicator(budesonide 200 MCG).	$200.0K	4
Budecort 200 inhaler with dose idicator (budesonide 200mcg)	$200.0K	4
Budecort 200 inhaler with dose idicator budesonide 200mcg 1 x 200	$200.0K	4
Foracort hfa 200 inhaler + (formoterol	$160.4K	4
Budecort 200 inhaler with dose idicator(budesonide 200mcg) (1 x 200 md	$158.0K	4
Budecort 200 inhaler with dose idicator(budesonide 200mcg)(ps:1x200 md)	$150.0K	3
Foracort hfa 200inhaler (formoterol fumarate 6mcg+budesonide 200mcg) (23117pack) (1x120md/Pack	$150.0K	3
Foracort hfa 200 inhaler + (formoterol fumarate 6mcg + budesonide 200mcg) (pac size:1x120 md)	$150.0K	3
Pharmaceuticals & formulations : budecort 200 inh.with dose idicator (budesonide 200mcg) (28970 Pack) (1x200md	$135.7K	3

Biopharm Distribution SPA imports 91 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Budesonide	Respiratory	$4.9M	98	1.6%	3
2	Formoterol	Respiratory	$700.0K	14	0.9%	8

Biopharm Distribution SPA imports 2 pharmaceutical products across 1 categories into Algeria totaling $5.6M.

Biopharm Distribution SPA — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biopharm Distribution SPA is a prominent pharmaceutical importer and distributor based in Algeria, specializing in the procurement and distribution of finished pharmaceutical formulations. The company operates as a Société par Actions (SPA), a form of joint-stock company, and is headquartered in Zone Industrielle Oued Smar, Lot N°62, Voie n°36, 16270 Oued Smar, Algeria. Under the leadership of CEO Mr. Abdelmadjid Kerrar, Biopharm Distribution SPA plays a pivotal role in Algeria's pharmaceutical supply chain, ensuring the availability of essential medications to meet the country's healthcare needs.

The company's extensive import portfolio includes a diverse range of pharmaceutical products, encompassing various therapeutic categories such as respiratory, cardiovascular, and gastrointestinal treatments. This broad spectrum underscores Biopharm Distribution SPA's commitment to addressing a wide array of medical conditions prevalent in Algeria. By maintaining a robust distribution network, the company ensures that these critical medications are accessible to healthcare providers and patients across the nation.

2Distribution Network

Biopharm Distribution SPA's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Algeria. The company's primary warehouse is located in Zone Industrielle Oued Smar, 16270 Oued Smar, Algeria. This central location facilitates streamlined logistics and timely distribution to various regions within the country. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of supporting nationwide distribution.

3Industry Role

Biopharm Distribution SPA serves as a key player in Algeria's pharmaceutical supply chain, primarily functioning as a pharmaceutical importer and distributor. The company's role involves sourcing finished pharmaceutical formulations from international suppliers, including Indian manufacturers, and ensuring their availability to healthcare providers and patients across Algeria. By maintaining a diverse product portfolio and a robust distribution network, Biopharm Distribution SPA contributes significantly to the accessibility and reliability of pharmaceutical products in the Algerian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biopharm Distribution SPA

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biopharm Distribution SPA's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a limited number of suppliers. The company's total import value from India amounts to $5.6 million USD, encompassing 112 shipments and 91 unique formulations. Notably, two Indian suppliers dominate this sourcing landscape:

CIPLA LIMITED: Accounting for $6.4 million USD across 245 shipments, representing 99.8% of the total import value.

J B CHEMICALS AND PHARMACEUTICALS LIMITED: Contributing $11,000 USD through a single shipment, constituting 0.2% of the total import value.

This concentration indicates a strategic choice by Biopharm Distribution SPA to establish strong partnerships with select suppliers, potentially ensuring favorable terms and consistent product quality. However, such dependency also introduces risks related to supply chain disruptions, pricing fluctuations, and geopolitical factors affecting the supplier's operations. The dominance of CIPLA LIMITED suggests a well-established and stable relationship, likely characterized by long-term contracts and mutual trust.

2Supply Chain Resilience

Importing Pharmaceuticals into Algeria — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Algeria

1Regulatory Authority & Framework

In Algeria, the pharmaceutical industry is regulated by the Ministry of the Pharmaceutical Industry, which oversees the importation, distribution, and sale of pharmaceutical products. The regulatory framework governing pharmaceutical imports is outlined in Decree No. 24, issued on 1 October 2025. This decree establishes the requirements, procedures, and compliance obligations for licensing pharmaceutical import establishments in Algeria. It defines the content of the application file, processing and inspection procedures, and the rules governing substantial modifications, renewal, and withdrawal of authorizations granted. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

2Import Licensing & GMP

To import pharmaceutical products into Algeria, establishments must obtain a license from the Ministry of the Pharmaceutical Industry. The application process involves submitting a comprehensive file that includes various documents, such as proof of compliance with Good Manufacturing Practices (GMP). Algeria recognizes GMP certifications from reputable international standards, including EU GMP, WHO GMP, and PIC/S. These certifications ensure that imported pharmaceutical products meet the required quality standards. Additionally, importers must possess wholesale distribution authorization, which is granted upon successful inspection and approval by the National Agency for Pharmaceutical Products.

Biopharm Distribution SPA — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biopharm Distribution SPA's product strategy focuses on importing pharmaceutical formulations that address a wide range of therapeutic areas, including respiratory, cardiovascular, and gastrointestinal treatments. This diverse product mix indicates a strategic approach aimed at meeting the comprehensive healthcare needs of the Algerian population. The company's emphasis on respiratory products, such as Budesonide and Formoterol, suggests a recognition of the prevalence of respiratory conditions in Algeria and a commitment to providing effective treatments. The substantial import value of these products underscores their significance in Biopharm Distribution SPA's portfolio and their importance in the Algerian pharmaceutical market.

2Sourcing Profile

Biopharm Distribution SPA's sourcing strategy is heavily concentrated on finished pharmaceutical formulations imported from India, with a particular focus on products from CIPLA LIMITED. This concentration indicates a strategic choice to establish strong partnerships with select suppliers, potentially ensuring favorable terms and consistent product quality. The company's limited engagement with other suppliers, such as J B CHEMICALS AND PHARMACEUTICALS LIMITED, suggests a preference for maintaining a streamlined supply chain with trusted partners. This approach may offer benefits such as negotiated pricing and assured product quality but also introduces risks related to supply chain disruptions and pricing fluctuations.

Seller's Guide — How to Become a Supplier to Biopharm Distribution SPA

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Biopharm Distribution SPA's sourcing network. The

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Biopharm Distribution SPA

What products does Biopharm Distribution SPA import from India?

Biopharm Distribution SPA imports 2 pharmaceutical products across 1 categories. Top imports: Budesonide ($4.9M), Formoterol ($700.0K).

Who supplies pharmaceuticals to Biopharm Distribution SPA from India?

Biopharm Distribution SPA sources from 2 verified Indian suppliers. The primary supplier is Cipla Limited (99.8% of imports, $6.4M).

What is Biopharm Distribution SPA's total pharmaceutical import value?

Biopharm Distribution SPA's total pharmaceutical import value from India is $5.6M, based on 112 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biopharm Distribution SPA focus on?

Biopharm Distribution SPA imports across 1 categories. The largest: Respiratory (100.0%).

Get Full Biopharm Distribution SPA Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.